Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409018 | 1.00 | KDR (0.45) | KDRFGFR1CHEK1LCKCDK4 | |
| SCHEMBL12895653 | 0.76 | ABL1 (0.45) | KDR | |
| SCHEMBL12895651 | 0.73 | ITK (0.48) | KDRFGFR1CHEK1CDK4CCND1 | |
| SCHEMBL6408124 | 0.70 | MAPT (0.37) | KDR | |
| SCHEMBL6408127 | 0.70 | MAPT (0.37) | KDR | |
| SCHEMBL6410604 | 0.68 | AURKA (0.47) | KDRFGFR1CHEK1CDK4CCND1 | |
| SCHEMBL6410600 | 0.68 | AURKA (0.47) | KDRFGFR1CHEK1CDK4CCND1 | |
| SCHEMBL2414215 | 0.62 | TP53 (0.49) | FGFR1AURKA | |
| SCHEMBL5247997 | 0.61 | KDR (1.00) | KDRFGFR1CHEK1LCKCDK4 | |
| SCHEMBL5247993 | 0.61 | KDR (1.00) | KDRFGFR1CHEK1LCKCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884123-B2 | 3-(1H-indol-2-yl)-1H-thieno[2,3-c]pyrazole-5-(N-phenoxycarboxamide); anticancer agents; protein kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-02-08 | — | — | US | disclosed |
| US-7884123-B2 | 3-(1H-indol-2-yl)-1H-thieno[2,3-c]pyrazole-5-(N-phenoxycarboxamide); anticancer agents; protein kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2011-02-08 | — | — | US | disclosed |
| US-20080058402-A1 | Substituted Thieno[2,3-c]pyrazoles, Process for Preparing Them, Compositions Containing Them, and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-03-06 | — | — | US | disclosed |
| US-20080058402-A1 | Substituted Thieno[2,3-c]pyrazoles, Process for Preparing Them, Compositions Containing Them, and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-03-06 | — | — | US | disclosed |
| US-20050026984-A1 | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products | AVENTIS PHARMA S.A. (FR) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026984-A1 | Substituted thieno [2,3-c] pyrazoles and their use as medicinal products | TPMT, PARK7, PRNP | KDR 3206/4885FGFR1 3825/4885CHEK1 474/4885 |
| US-20080058402-A1 | Substituted Thieno[2,3-c]pyrazoles, Process for Preparing Them, Compositions Containing Them, and Use Thereof | TYMS, TYMP, CYP3A43 | KDR 2229/4885FGFR1 3035/4885CHEK1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.